The Evolving Science and Medicine
of Myelodysplastic Syndromes

WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Release Date:

June 30, 2009

Expiration Date:

June 30, 2011

Intended Audience:

The educational activity is designed for all physicians, acade micians, researchers, investigators, support staff, nurses, and program directors from the fields hematology and oncology.

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

The following program has been supported
by an independent medical educational grant
from Eisai, Inc.

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essentials Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 3 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Policy on Faculty Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosures:

Frederick R. Appelbaum, MD– Program Chairman
Director, Clinical Research
Fred Hutchinson Cancer Research Center
Professor of Medicine and Head
Division of Medical Oncology
University of Washington
School of Medicine
Seattle, WA
Nothing to Disclose

Jaroslaw Maciejewski, MD, PhD
Translation Hematology and Oncology Research
Department Chair
The Cleveland Clinic
Professor of Medicine
Cleveland Clinic Lerner College of Medicine at
Case Western Reserve University
Cleveland, OH
Nothing to Disclose

Richard M. Stone, MD
Professor of Medicine
Harvard Medical School
Director, Adult Leukemia Program
Dana-Farber Cancer Institute
Boston, MA
Nothing to Disclose

Guillermo Garcia-Manero, MD
Associate Professor of Medicine
Chief of the Section of Myelodysplastic Syndromes
Department of Leukemia
The University of Texas M.D. Anderson Cancer Center
Houston, TX
Nothing to Disclose

Educational Objectives:

As a result of participating in this program, clinicians from multiple disciplines, including oncology, hematology, surgical oncology, cancer supportive care, cancer nursing, internal medicine, clinical pharmacy, and related specialties will:

• Learn how to deliver evidence- and expert-generated therapy for MDS, based on the stage, severity, and disease karyotype.

• Learn about the safety, efficacy, survival, complications, adverse effects, and indications for cytotoxic agents used for MDS.

• Learn about the safety, efficacy, survival, complications, adverse effects, and indications for hypomethylating and immune modulating agents used and indicated for MDS.

• Learn how to approach to difficult-to-treat patients, including those with unfavorable karyotype (i.e. complex karyotypes or monosomy 7).

• Learn how to assess optimal triggers to timing for bone transplantation, with a focus on level of remission and pretreatment with single or combination agents prior to transplant.

• Learn about the implications of studies evaluating single and combination cytotoxic chemotherapy in patients with MDS.
  

Disclaimer:

Copyright © 2009 by CMEducation Resources, LLC and Pharmatecture, LLC All rights reserved. Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this WebCAST reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this WebCAST is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this WebCAST is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This WebCAST is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This WebCAST is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2009 All rights reserved